TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects
Brief Summary: The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.


Options:
A: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A
C: Arm Label: NB16; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Ancillary therapy | Intervention Type: DRUG; Name: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB16 | Intervention Type: DRUG; Name: Naltrexone SR 32 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Ancillary therapy; Assigned to Arm(s): NB16, NB32, Placebo
D: Arm Label: VI-0521 Top; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: VI-0521 Mid; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: VI-0521 | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Top | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Mid | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial
Brief Summary: Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red blood cell density and the frequency of pain episodes in people with HbSC.


Options:
A: Arm Label: Magnesium group; Type: EXPERIMENTAL; Interventions: Drug: Intravenous Magnesium Sulfate | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline Placebo | Intervention Type: DRUG; Name: Intravenous Magnesium Sulfate; Assigned to Arm(s): Magnesium group | Intervention Type: DRUG; Name: Normal Saline Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid
C: Arm Label: Stage 1; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 2; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 3; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 4; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 2B; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Intervention Type: DRUG; Name: Lexiscan; Assigned to Arm(s): Stage 1, Stage 2, Stage 2B, Stage 3, Stage 4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial
Brief Summary: Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red blood cell density and the frequency of pain episodes in people with HbSC.


Options:
A: Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm
B: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid
C: Arm Label: Standard Therapy: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea
D: Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial
Brief Summary: Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red blood cell density and the frequency of pain episodes in people with HbSC.


Options:
A: Arm Label: Magnesium group; Type: EXPERIMENTAL; Interventions: Drug: Intravenous Magnesium Sulfate | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline Placebo | Intervention Type: DRUG; Name: Intravenous Magnesium Sulfate; Assigned to Arm(s): Magnesium group | Intervention Type: DRUG; Name: Normal Saline Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: Stage 1; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 2; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 3; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 4; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 2B; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Intervention Type: DRUG; Name: Lexiscan; Assigned to Arm(s): Stage 1, Stage 2, Stage 2B, Stage 3, Stage 4
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial
Brief Summary: Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red blood cell density and the frequency of pain episodes in people with HbSC.


Options:
A: Arm Label: MTD Dose Escalation; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Fixed Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Fixed Dose, MTD Dose Escalation
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1
C: Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Critical Limb Ischemia Treatment by Local Intra-Muscular Injection of Autologous Mononuclear Cells
Brief Summary: The primary focus of the trial is safety and efficacy of the intra-muscular implantation of either bone-marrow, or peripheral blood mononuclear cells, in critical limb ischemia, as judged by the proportion of patients which are alive without major amputation 6 months after inclusion.


Options:
A: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC
B: Arm Label: A: GM-CSF + supervised treadmill exercise therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Treadmill Exercise Therapy, Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: B: GM-CSF + attention control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions (Control), Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: C: placebo + supervised exercise therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Treadmill Exercise Therapy | Arm Label: D: placebo + attention control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health education sessions (Control) | Intervention Type: BEHAVIORAL; Name: Supervised Treadmill Exercise Therapy; Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, C: placebo + supervised exercise therapy | Intervention Type: OTHER; Name: Health education sessions (Control); Assigned to Arm(s): B: GM-CSF + attention control group, D: placebo + attention control group | Intervention Type: DRUG; Name: granulocyte macrophage colony stimulating factor (GM-CSF); Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, B: GM-CSF + attention control group
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Critical Limb Ischemia Treatment by Local Intra-Muscular Injection of Autologous Mononuclear Cells
Brief Summary: The primary focus of the trial is safety and efficacy of the intra-muscular implantation of either bone-marrow, or peripheral blood mononuclear cells, in critical limb ischemia, as judged by the proportion of patients which are alive without major amputation 6 months after inclusion.


Options:
A: Arm Label: ALD-301; Type: EXPERIMENTAL; Interventions: Biological: ALD-301 | Arm Label: Placebo (vehicle); Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (vehicle) | Intervention Type: BIOLOGICAL; Name: ALD-301; Assigned to Arm(s): ALD-301 | Intervention Type: BIOLOGICAL; Name: Placebo (vehicle); Assigned to Arm(s): Placebo (vehicle)
B: Arm Label: Autologous Bone Marrow Mononuclear Cells; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells; Assigned to Arm(s): Autologous Bone Marrow Mononuclear Cells
C: Arm Label: mesenchymal stem cells; Type: EXPERIMENTAL; Interventions: Drug: mesenchymal stem cells | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Plasmalyte A | Intervention Type: DRUG; Name: mesenchymal stem cells; Assigned to Arm(s): mesenchymal stem cells | Intervention Type: DRUG; Name: Plasmalyte A; Assigned to Arm(s): Placebo
D: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Critical Limb Ischemia Treatment by Local Intra-Muscular Injection of Autologous Mononuclear Cells
Brief Summary: The primary focus of the trial is safety and efficacy of the intra-muscular implantation of either bone-marrow, or peripheral blood mononuclear cells, in critical limb ischemia, as judged by the proportion of patients which are alive without major amputation 6 months after inclusion.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow derived mononuclear cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow derived mononuclear cells | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: bone marrow derived mononuclear cells; Assigned to Arm(s): 1, 3 | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): 2, 4
C: Arm Label: Active/Treatment Group; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic bone marrow derived mesenchymal stem cells | Arm Label: Observation Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 3; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Group 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Allogeneic bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Active/Treatment Group
D: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Critical Limb Ischemia Treatment by Local Intra-Muscular Injection of Autologous Mononuclear Cells
Brief Summary: The primary focus of the trial is safety and efficacy of the intra-muscular implantation of either bone-marrow, or peripheral blood mononuclear cells, in critical limb ischemia, as judged by the proportion of patients which are alive without major amputation 6 months after inclusion.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Intervention Type: PROCEDURE; Name: intraarterial stem cell therapy; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Stem cells; Assigned to Arm(s): 1, 2
B: Intervention Type: PROCEDURE; Name: cell therapy; Assigned to Arm(s): N/A
C: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: bone marrow stem cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Arm Label: tissue repair cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: tissue repair cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: bone marrow stem cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Intervention Type: BIOLOGICAL; Name: tissue repair cells (TRC); Assigned to Arm(s): tissue repair cells intraarterial, tissue repair cells intramuscular | Intervention Type: BIOLOGICAL; Name: bone marrow stem cells (BMC); Assigned to Arm(s): bone marrow stem cells intraarterial, bone marrow stem cells intramuscular
D: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC

Answer: D